Zhong Guo Jing Ji Wang·2025-08-19 09:05Core Viewpoint - BGI Genomics (688114.SH) is currently experiencing a decline in stock price, closing at 69.60 yuan with a drop of 2.15%, indicating that the stock is in a state of underperformance since its IPO [1] Fundraising and Financials - BGI Genomics was listed on the Shanghai Stock Exchange's STAR Market on September 9, 2022, with an issuance of 41,319,475 shares at a price of 87.18 yuan per share, currently trading below the IPO price [1] - The total amount raised by BGI Genomics was 3,602.23 million yuan, with a net amount of 3,284.55 million yuan after deducting issuance costs, which exceeded the original plan by 756.71 million yuan [1] - The company aimed to raise 2,527.85 million yuan for various projects, including smart manufacturing and R&D base, semiconductor-based gene sequencers, R&D center, marketing service center, information system construction, and working capital [1] Underwriting and Costs - The lead underwriter for BGI Genomics was CITIC Securities Co., Ltd., with representatives Xiao Shaochun and Lu Ming, while the co-underwriters included China International Capital Corporation and UBS Securities [1] - The total issuance costs amounted to 317.68 million yuan, with underwriting and sponsorship fees accounting for 271.54 million yuan [1]